Covered recipient · General Payments record
WILLIAM L JOHNSON
Allopathic & Osteopathic Physicians Pediatrics Pediatric Allergy/Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,663.83
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,663.83 | 103 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $312.12 | 19 |
| GlaxoSmithKline, LLC. | $281.18 | 21 |
| kaleo, Inc. | $184.42 | 10 |
| CSL Behring | $143.73 | 8 |
| GENZYME CORPORATION | $119.42 | 7 |
| Takeda Pharmaceuticals U.S.A., Inc. | $98.19 | 7 |
| PFIZER INC. | $97.93 | 6 |
| Covis Pharma GmBH | $56.55 | 3 |
| Novartis Pharmaceuticals Corporation | $56.31 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $43.32 | 3 |
| Optinose US, Inc. | $41.21 | 3 |
| Grifols USA, LLC | $38.29 | 2 |
| Regeneron Healthcare Solutions, Inc. | $36.49 | 2 |
| Genentech USA, Inc. | $35.25 | 2 |
| AIMMUNE THERAPEUTICS, INC. | $22.19 | 1 |
| Teva Pharmaceuticals USA, Inc. | $18.89 | 1 |
| ADMA BioManufacturing LLC | $17.78 | 1 |
| Merck Sharp & Dohme Corporation | $17.32 | 1 |
| BioCryst US Sales Co., LLC | $16.09 | 1 |
| Stryker Corporation | $15.21 | 1 |
| Amgen Inc. | $11.94 | 1 |
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM L JOHNSON
NPI 1669476495 · CMS profile ID 302077
Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Allergy/Immunology
SAINT LOUIS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $1,663.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–103 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $14.43 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829568497 | CMS |
| AstraZeneca Pharmaceuticals LP | $40.19 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829781569 | CMS |
| Grifols USA, LLC | $20.78 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846777369 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $741,690.33 | 83 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
83 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 12/22/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158198 |
| Principal investigator 1 | Genentech, Inc. | $7,944.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625658 |
| Principal investigator 1 | Genentech, Inc. | $156.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625661 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625666 |
| Principal investigator 1 | Genentech, Inc. | $624.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625671 |
| Principal investigator 1 | Genentech, Inc. | $255.45 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625675 |
| Principal investigator 1 | Genentech, Inc. | $269.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625678 |
| Principal investigator 1 | Genentech, Inc. | $1,268.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625681 |
| Principal investigator 1 | Genentech, Inc. | $1,031.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625685 |
| Principal investigator 1 | Genentech, Inc. | $1,101.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625687 |
| Principal investigator 1 | Genentech, Inc. | $2,639.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625693 |
| Principal investigator 1 | Genentech, Inc. | $260.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625698 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625703 |
| Principal investigator 1 | Genentech, Inc. | $324.00 | 12/16/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211625707 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,070.27 | 12/11/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047572 |
| Principal investigator 1 | Genentech, Inc. | $14,029.00 | 11/21/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625642 |
| Principal investigator 1 | Genentech, Inc. | $19,532.00 | 11/21/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625645 |
| Principal investigator 1 | Genentech, Inc. | $510.00 | 11/20/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625634 |
| Principal investigator 1 | Genentech, Inc. | $2,639.00 | 11/20/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625638 |
| Principal investigator 1 | Genentech, Inc. | $5,353.00 | 11/20/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625648 |
| Principal investigator 1 | Genentech, Inc. | $312.00 | 11/20/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625654 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,896.17 | 11/20/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047570 |
| Principal investigator 1 | Verona Pharma, Inc. | $8,181.21 | 11/19/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891557 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,489.00 | 11/17/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158195 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,605.00 | 10/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185549823 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,044.60 | 10/06/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158190 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625598 |
| Principal investigator 1 | Genentech, Inc. | $590.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625601 |
| Principal investigator 1 | Genentech, Inc. | $404.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625606 |
| Principal investigator 1 | Genentech, Inc. | $3,972.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625612 |
| Principal investigator 1 | Genentech, Inc. | $354.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625615 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625622 |
| Principal investigator 1 | Genentech, Inc. | $413.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625624 |
| Principal investigator 1 | Genentech, Inc. | $404.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625627 |
| Principal investigator 1 | Genentech, Inc. | $312.00 | 10/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625631 |
| Principal investigator 1 | Genentech, Inc. | $26,215.00 | 10/01/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625618 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $263.25 | 09/25/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047566 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,904.56 | 09/25/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047568 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,344.00 | 09/22/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158188 |
| Principal investigator 1 | Genentech, Inc. | $11,986.00 | 09/09/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625596 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,615.40 | 09/08/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 | No dispute reported | 06/30/2026 | 1226158176 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,989.00 | 09/08/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158184 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $450.00 | 08/21/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047564 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,443.89 | 08/19/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047562 |
| Principal investigator 1 | Verona Pharma, Inc. | $9,500.00 | 08/15/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891501 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,750.00 | 08/15/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891503 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,896.00 | 08/11/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158172 |
| Principal investigator 1 | Genentech, Inc. | $36,361.00 | 08/05/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625591 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,101.55 | 07/25/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047560 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,617.99 | 07/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047558 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $501.00 | 07/14/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158138 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,726.00 | 07/14/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158143 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,832.05 | 06/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047552 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $539.33 | 06/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047554 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,809.12 | 06/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047556 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,029.70 | 06/23/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158134 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,930.00 | 06/16/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158106 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,782.00 | 06/16/2025 | Non-covered Recipient Entity Midwest Clinical Research Center St Louis | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226158116 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,493.05 | 06/05/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047550 |
| Principal investigator 1 | Genentech, Inc. | $3,125.00 | 06/03/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625530 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 06/03/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625537 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 06/03/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625582 |
| Principal investigator 1 | Genentech, Inc. | $1,919.70 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625527 |
| Principal investigator 1 | Genentech, Inc. | $454.98 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625540 |
| Principal investigator 1 | Genentech, Inc. | $1,100.00 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625547 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625550 |
| Principal investigator 1 | Genentech, Inc. | $2,817.00 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625555 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625561 |
| Principal investigator 1 | Genentech, Inc. | $2,639.00 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625572 |
| Principal investigator 1 | Genentech, Inc. | $241.17 | 05/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625588 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,699.45 | 04/24/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047548 |
| Principal investigator 1 | AstraZeneca UK Limited | $31,293.98 | 04/14/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185549829 |
| Principal investigator 1 | Genentech, Inc. | $3,263.10 | 04/10/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625564 |
| Principal investigator 1 | Genentech, Inc. | $365.86 | 04/10/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625567 |
| Principal investigator 1 | Genentech, Inc. | $156.00 | 04/10/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625577 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,051.80 | 04/09/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH | A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease | No dispute reported | 06/30/2026 | 1185549825 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $125,341.07 | 03/14/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185549827 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,834.72 | 02/27/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047546 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047578 |
| Principal investigator 1 | Genentech, Inc. | $12,012.00 | 02/18/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625518 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,617.99 | 01/30/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047544 |
| Principal investigator 1 | Eli Lilly and Company | $239,517.32 | 01/08/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187885324 |
| Principal investigator 1 | Genentech, Inc. | $12,914.00 | 01/02/2025 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH LLC | Ph IIb of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211625522 |